-
Innovation Ranking
Innovation Ranking – TG Therapeutics Inc
TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and various autoimmune diseases. The company’s approved products in the US include Ukoniq for the treatment of relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma. The pipeline products of the company include TG-1701 and TG-1801 for the treatment of B-cell cancers and other diseases. The company also evaluates products and technologies for in-licensing, partnership,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-01 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-01 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-01 in Pancreatic Cancer Drug Details: TG-01 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-01 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-01 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-01 in Pancreatic Ductal Adenocarcinoma Drug Details: TG-01 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-1042 in Cutaneous B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-1042 in Cutaneous B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-1042 in Cutaneous B-Cell Lymphoma Drug Details: TG-1042 (ASN-002) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-01 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-01 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-01 in Non-Small Cell Lung Cancer Drug Details: TG-01...
-
Product Insights
Likelihood of Approval Analysis for Heterozygous familial hypercholesterolemia (heFH)
Overview How likely is it that the drugs in Heterozygous familial hypercholesterolemia (heFH) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Heterozygous familial hypercholesterolemia (heFH) Overview Heterozygous familial hypercholesterolemia (HeFH) is...
-
Analyst Opinions
NewOnline Gambling in Greater China – Patent and Company Insights, Key Trends and Challenges
Online Gambling in Greater China Report Overview In Greater China, the trends in online gambling patents showcase innovative advancements, particularly focusing on enhancing user experience through the integration of virtual reality (VR) and Internet of Things (IoT) technologies. Additionally, these patents aim to improve operational efficiency within lotteries while ensuring fair play and security through the implementation of blockchain technology and advanced ticketing systems. The ’Online Gambling in Greater China’ research report dives into the key patent trends and active...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Saroglitazar in Hypertriglyceridemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Hypertriglyceridemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saroglitazar in Hypertriglyceridemia Drug Details: Saroglitazar (lipaglyn) is the first Glitazar having...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Saroglitazar in Cholestasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Cholestasis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saroglitazar in Cholestasis Drug Details: Saroglitazar (lipaglyn) is the first Glitazar having...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Saroglitazar in Liver Diseases
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Liver Diseases report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saroglitazar in Liver Diseases Drug Details: Saroglitazar (lipaglyn) is the first...